See also this year's filing and all EDGAR filings for this company.
PDF Report 0001367644_2022_Emergent_BioSolutions_Inc.pdf
Logs
| warning | Large missing amount for aggregate "Revenues" added to remainder. | industry.us_generic | {'missing_ratio': inf, 'aggregate_val': 1792700000, 'exp_sum': 0, 'exp_to_value': {'remainder_Revenues': 0}} |
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 0.9887743114475916, 'aggregate_val': 1523600000, 'exp_sum': 766100000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 348400000, 'ResearchAndDevelopmentExpense': 234000000, 'remainder_Expenses': 183700000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001367644, Emergent BioSolutions Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 1,272,100,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 829,500,000 |
| 2 | PropertyPlantAndEquipmentNet | 800,100,000 |
| 3 | remainder_Assets | 57,300,000 |
| 4 | LiabilitiesCurrent | 373,800,000 |
| 5 | LiabilitiesNoncurrent | 866,800,000 |
| 6 | remainder_Liabilities | 99,400,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 348,400,000 |
| 9 | ResearchAndDevelopmentExpense | 234,000,000 |
| 10 | remainder_Expenses | 941,200,000 |
| 11 | remainder_Revenues | 1,792,700,000 |
| 12 | remainder_NetIncome | -38,200,000 |
| 13 | remainder_ComprehensiveNetIncome | 9,200,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 2,959,000,000 |
| 1 | Liabilities | 1,340,000,000 |
| 2 | Expenses | 1,523,600,000 |
| 3 | Revenues | 1,792,700,000 |
| 4 | StockholdersEquity | 1,619,000,000 |
| 5 | NetIncome | 230,900,000 |
| 6 | ComprehensiveNetIncome | 235,500,000 |
| 7 | BaseVar | 3,831,350,000 |
| 8 | EconomicCapitalRatio | 1.41 |
Edgar->Model Mapping
Feature Distribution
Change over Time
